Examples include ADA-deficiency treatment with genetically modified CD34+ blood cells or junctional epidermolysis bullosa therapy with LM5-beta 3-transduced epidermal cells, after approximately 10 years of follow-up in both cases [6, 14, 17]. This evidence concerns the gene ADA and Junctional epidermolysis bullosa, Herlitz type.